HC Wainwright Issues Pessimistic Estimate for FDMT Earnings

4D Molecular Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its FY2026 EPS estimate for 4D Molecular Therapeutics to a loss of $4.20 per share from $4.08, while maintaining a Buy rating and a $36 price target. Its new forecast is slightly more pessimistic than the $4.18-per-share loss consensus.
  • In its latest quarter, the company reported an EPS loss of $1.08, missing the $1.05-loss consensus, while revenue of $4.14 million narrowly exceeded estimates of $4.13 million.
  • Analyst sentiment is mostly positive: 10 analysts rate FDMT a Buy and one a Sell, with a consensus “Moderate Buy” rating and an average price target of $30.22.
  • Five stocks to consider instead of 4D Molecular Therapeutics.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a report released on Monday, November 16th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($4.20) per share for the year, down from their prior forecast of ($4.08). HC Wainwright has a "Buy" rating and a $36.00 price target on the stock. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($4.18) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics' Q4 2026 earnings at ($1.07) EPS, FY2027 earnings at ($4.43) EPS, FY2028 earnings at ($4.74) EPS, FY2029 earnings at ($3.58) EPS and FY2030 earnings at ($1.75) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.03). The business had revenue of $4.14 million for the quarter, compared to the consensus estimate of $4.13 million. 4D Molecular Therapeutics had a negative return on equity of 47.06% and a negative net margin of 208.57%.

Other research analysts also recently issued research reports about the stock. Bank of America raised their price target on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the stock a "buy" rating in a research note on Tuesday, September 29th. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday, October 15th. B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a "neutral" rating to an "overweight" rating and set a $20.00 price target for the company in a research note on Monday, September 14th. Finally, The Goldman Sachs Group reiterated a "buy" rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $30.22.

Check Out Our Latest Stock Report on FDMT

4D Molecular Therapeutics Trading Down 4.4%

NASDAQ FDMT opened at $10.79 on Wednesday. The company's 50-day moving average price is $12.99 and its 200-day moving average price is $11.09. The company has a current ratio of 6.15, a quick ratio of 6.15 and a debt-to-equity ratio of 0.06. The stock has a market cap of $608.34 million, a PE ratio of -4.00 and a beta of 2.92. 4D Molecular Therapeutics has a 12 month low of $6.96 and a 12 month high of $16.93.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Jupiter Topco LLC bought a new position in 4D Molecular Therapeutics in the second quarter worth approximately $76,466,000. Janus Henderson Group PLC lifted its holdings in 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company's stock worth $48,868,000 after buying an additional 611,276 shares during the period. BlackRock Inc. bought a new stake in 4D Molecular Therapeutics during the 2nd quarter valued at $60,463,000. Trails Edge Capital Partners LP bought a new stake in 4D Molecular Therapeutics during the 2nd quarter valued at $29,631,296. Finally, Bank of America Corp DE purchased a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $14,905,000. Hedge funds and other institutional investors own 99.27% of the company's stock.

Insider Buying and Selling at 4D Molecular Therapeutics

In related news, insider David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $12.92, for a total value of $753,662.36. Following the completion of the sale, the insider directly owned 709,153 shares in the company, valued at $9,162,256.76. The trade was a 7.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 120,520 shares of company stock valued at $1,615,978 in the last ninety days. Insiders own 7.90% of the company's stock.

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company's proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.

Read More

Earnings History and Estimates for 4D Molecular Therapeutics (NASDAQ:FDMT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?

Before you consider 4D Molecular Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.

While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines